跳转到内容

Die kontinuierliche Medicaid-Berechtigung während der PHE verbesserte die Absicherung nach der Geburt

13. März 2024 – Laut einer im JAMA Health Forum veröffentlichten Studie war die kontinuierliche Anspruchsvoraussetzung für Medicaid während des COVID-19-Notstands im Bereich der öffentlichen Gesundheit mit einer erhöhten Zahl postpartaler Medicaid-Registrierungen und einer geringeren Nichtversicherung verbunden. Eine Krankenversicherung kann dazu beitragen, den Zugang zu körperlicher und geistiger Gesundheitsversorgung nach der Geburt sicherzustellen. Das Bundesgesetz […] Die kontinuierliche Medicaid-Berechtigung während der PHE verbesserte die Absicherung nach der Geburt

Risiko Bioterrorismus. Foto: Pexels.com

STSS: Die Fakten

Medien berichten von STSS in Japan und vergleichen den aktuellen Ausbruch mit der COVID-19 Pandemie. Das ist schlichtweg falsch – denn STSS ist keine Virusinfektion. Das Streptokokken-Toxische-Schock-Syndrom (STSS) ist eine seltene, aber schwerwiegende bakterielle Infektion. STSS kann sich sehr schnell zu niedrigem Blutdruck, Multiorganversagen und sogar zum Tod entwickeln. Bakterien, die als Streptokokken der Gruppe A (Strep der Gruppe A) bezeichnet werden, können STSS verursachen, wenn sie sich in tiefe Gewebe und den Blutkreislauf ausbreiten. Bei fast der Hälfte der Menschen, die an STSS erkranken, wissen Experten nicht, wie die Bakterien in den Körper gelangten. Manchmal gelangen die Bakterien durch Öffnungen in der Haut in den Körper, beispielsweise durch eine Verletzung oder eine Operationswunde. Die Bakterien können auch über Schleimhäute in den Körper gelangen, beispielsweise über die Haut im Nasen- und Rachenraum. Es kommt sehr selten vor, dass jemand mit… 

more »STSS: Die Fakten

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, March 15, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from the University of Calgary’s Cumming School of Medicine has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver. University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11, 2024, it received two letters from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”), one notifying the Company (the “MVLS Notice”) that for the last 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “Market Value Standard”), and the other notifying the Company (the “MVPHS Notice”) that for the last 30 consecutive business days, the Company’s Market Value of Publicly Held Shares (“MVPHS”) was below the minimum of $15 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Standard”). Psyence Biomedical Ltd.… 

more »Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares

Oncternal 参与关于前列腺癌治疗格局和新治疗方案的意见领袖线上炉边谈话

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer. Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

Oncternal 参与关于前列腺癌治疗格局和新治疗方案的意见领袖线上炉边谈话

SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will participate in a virtual fireside chat on the Treatment Landscape & New Treatment Options for Prostate Cancer. Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.

PALO ALTO, Calif., March 15, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it received Halal Certification of its commercial product ZTlido, indicating that ZTlido has undergone rigorous assessment to determine that it is permissible or acceptable in accordance with Islamic standards. The Halal certification was issued under the authority of Circle H International, Inc. (“Circle H”) and offers the Company the opportunity to provide ZTlido to Islamic markets globally. This announcement supports the global expansion strategy for Scilex, which Scilex anticipates will include a presence in the Middle East and North Africa (MENA) region with an initial priority focus on the UAE and Saudi Arabia. Scilex Holding Announces Issuance… 

more »Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.

BioXcel Therapeutics 宣布欧洲专利局授予一项关于使用舌下右美托咪定治疗痴呆症激越方法的专利

Newly granted patent aligns with Company’s focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501 Newly granted patent aligns with Company’s focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501 The post BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual… BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

COVID-19 may have originated in a lab

The origin of COVID-19 is highly debated – most studies have focused on a zoonotic origin, but research from the journal Risk Analysis, examined the likelihood of an unnatural origin (i.e. from a laboratory.) The results indicate a greater likelihood of an unnatural than natural origin of the virus. The researchers used an established risk analysis tool for differentiating natural and unnatural epidemics, the modified Grunow-Finke assessment tool (mGFT) to study the origin of COVID-19. This risk assessment cannot prove the specific origin of COVID-19 but shows that the possibility of a laboratory origin cannot be easily dismissed. https://onlinelibrary.wiley.com/doi/full/10.1111/risa.14291

Online-Investitionsbetrug: In einer gefälschten Handelsplattform

Online-Investitionsbetrug ist ein globales, wachsendund eine einzigartig schädliche Bedrohung. In neu veröffentlichten Daten führte die Federal Trade Commission mehr als 4,6 Milliarden US-Dollar an Betrugsverlusten in den USA im Jahr 2023 auf Investitionsbetrug zurück, mehr als jede andere Betrugskategorie, und einen Anstieg von 21 % im Jahr 2022. Der Internet Crime Report 2023 des FBI […] Online-Investitionsbetrug: In einer gefälschten Handelsplattform